[
	{
		"gene_name": "EGFR",
		"variant_name": "S768I",
		"HGVScoding": "NM_005228.4:c.2303G>T",
		"HGVSprotein": "NP_005219.2:p.Ser768Ile",
		"position": "GrCh37:chr7:55249005",
		"molecular_consequence": "NON_SYNONYMOUS, NONCODING_CHANGE",
		"tier_level": "1B",
		"dbSNP": "rs121913465",
		"SVIP_status": "Curated",
		"SVIP_confidence_score": 4,
		"variant_id": 145,
		"diseases": [
			{
				"name": "non-small cell lung carcinoma",
				"nb_patients": "88/144",
				"age_distribution": {
					"<40": 5,
					"41-60": 30,
					"61-80": 50,
					">80": 3
				},
				"gender_balance": {
					"male": 60,
					"female": 40
				},
				"pathogenicity": "pathogenic",
				"pathogenicity_level": "automatic",
				"SVIP_status": "Curated",
				"clinical_significance": "predictive",
				"significance_label": "B",
				"score": 3,
				"evidences": [
					{
						"drug": "",
						"evidence_type": "prognostic",
						"clinical_significance": "poor outcome",
						"tier_level": "Tier II"
					},
					{
						"drug": "Erlotinib",
						"evidence_type": "predictive",
						"clinical_significance": "sensitive",
						"tier_level": "Tier I"
					}
				]
			},
			{
				"name": "lung adenocarcinoma",
				"nb_patients": "56/144",
				"age_distribution": {
					"<40": 10,
					"41-60": 23,
					"61-80": 18,
					">80": 5
				},
				"gender_balance": {
					"male": 65,
					"female": 35
				},
				"pathogenicity": "pathogenic",
				"pathogenicity_level": "expert",
				"SVIP_status": "Reviewed",
				"clinical_significance": "predictive / prognostic",
				"significance_label": "A",
				"score": 4,
				"evidences": [
					{
						"drug": "Afatinib",
						"evidence_type": "predictive",
						"clinical_significance": "sensitive",
						"tier_level": "Tier I"
					}
				]
			}
		]
	},
	{
		"gene_name": "EGFR",
		"variant_name": "T790M",
		"HGVScoding": "NM_005228.4:c.2369C>T",
		"HGVSprotein": "NP_005219.2:p.Thr790Met",
		"position": "GrCh37:chr7:55249071",
		"molecular_consequence": "NON_SYNONYMOUS, NONCODING_CHANGE, REGULATORY",
		"tier_level": "1B",
		"dbSNP": "rs121434569",
		"SVIP_status": "Loaded",
		"SVIP_confidence_score": 3,
		"variant_id": 130,
		"diseases": [
			{
				"name": "non-small cell lung carcinoma",
				"nb_patients": "88/144",
				"age_distribution": {
					"<40": 5,
					"41-60": 30,
					"61-80": 50,
					">80": 3
				},
				"gender_balance": {
					"male": 60,
					"female": 40
				},
				"pathogenicity": "pathogenic",
				"pathogenicity_level": "automatic",
				"SVIP_status": "Curated",
				"clinical_significance": "predictive",
				"significance_label": "B",
				"score": 3,
				"evidences": [
					{
						"drug": "",
						"evidence_type": "prognostic",
						"clinical_significance": "poor outcome",
						"tier_level": "Tier II"
					},
					{
						"drug": "Erlotinib",
						"evidence_type": "predictive",
						"clinical_significance": "sensitive",
						"tier_level": "Tier I"
					}
				]
			},
			{
				"name": "lung adenocarcinoma",
				"nb_patients": "56/144",
				"age_distribution": {
					"<40": 10,
					"41-60": 23,
					"61-80": 18,
					">80": 5
				},
				"gender_balance": {
					"male": 65,
					"female": 35
				},
				"pathogenicity": "pathogenic",
				"pathogenicity_level": "expert",
				"SVIP_status": "Reviewed",
				"clinical_significance": "predictive / prognostic",
				"significance_label": "A",
				"score": 4,
				"evidences": [
					{
						"drug": "Afatinib",
						"evidence_type": "predictive",
						"clinical_significance": "sensitive",
						"tier_level": "Tier I"
					}
				]
			}
		]
	},
	{
		"gene_name": "EGFR",
		"variant_name": "L858R",
		"HGVScoding": "NM_005228.4:c.2573T>G",
		"HGVSprotein": "NP_005219.2:p.Leu858Arg",
		"position": "GrCh37:chr7:55259515",
		"molecular_consequence": "NON_SYNONYMOUS",
		"tier_level": "1A",
		"dbSNP": "rs121434568",
		"SVIP_status": "Reviewed",
		"SVIP_confidence_score": 3,
		"variant_id": 142,
		"diseases": [
			{
				"name": "non-small cell lung carcinoma",
				"nb_patients": "88/144",
				"age_distribution": {
					"<40": 5,
					"41-60": 30,
					"61-80": 50,
					">80": 3
				},
				"gender_balance": {
					"male": 60,
					"female": 40
				},
				"pathogenicity": "pathogenic",
				"pathogenicity_level": "automatic",
				"SVIP_status": "Curated",
				"clinical_significance": "predictive",
				"significance_label": "B",
				"score": 3,
				"evidences": [
					{
						"drug": "",
						"evidence_type": "prognostic",
						"clinical_significance": "poor outcome",
						"tier_level": "Tier II"
					},
					{
						"drug": "Erlotinib",
						"evidence_type": "predictive",
						"clinical_significance": "sensitive",
						"tier_level": "Tier I"
					}
				]
			},
			{
				"name": "lung adenocarcinoma",
				"nb_patients": "56/144",
				"age_distribution": {
					"<40": 10,
					"41-60": 23,
					"61-80": 18,
					">80": 5
				},
				"gender_balance": {
					"male": 65,
					"female": 35
				},
				"pathogenicity": "pathogenic",
				"pathogenicity_level": "expert",
				"SVIP_status": "Reviewed",
				"clinical_significance": "predictive / prognostic",
				"significance_label": "A",
				"score": 4,
				"evidences": [
					{
						"drug": "Afatinib",
						"evidence_type": "predictive",
						"clinical_significance": "sensitive",
						"tier_level": "Tier I"
					}
				]
			}
		]
	},
	{
		"gene_name": "BRAF",
		"variant_name": "G596R",
		"HGVScoding": "NM_004333.4:c.1786G>C",
		"HGVSprotein": "NP_004324.2:p.Gly596Arg",
		"position": "GrCh37:chr7:140453149",
		"molecular_consequence": "NON_SYNONYMOUS",
		"tier_level": 3,
		"dbSNP": "rs121913361",
		"SVIP_status": "Loaded",
		"SVIP_confidence_score": 2,
		"variant_id": 56,
		"diseases": [
			{
				"name": "Papillary thyroid carcinoma",
				"nb_patients": "88/144",
				"age_distribution": {
					"<40": 5,
					"41-60": 30,
					"61-80": 50,
					">80": 3
				},
				"gender_balance": {
					"male": 60,
					"female": 40
				},
				"pathogenicity": "pathogenic",
				"pathogenicity_level": "automatic",
				"SVIP_status": "Curated",
				"clinical_significance": "predictive",
				"significance_label": "B",
				"score": 3,
				"evidences": [
					{
						"drug": "",
						"evidence_type": "Prognostic",
						"clinical_significance": "Poor outcome",
						"tier_level": "Tier II"
					},
					{
						"drug": "Vemurafenib",
						"evidence_type": "predictive",
						"clinical_significance": "sensitive",
						"tier_level": "Tier II"
					}
				]
			},
			{
				"name": "colorectal cancer",
				"nb_patients": "56/144",
				"age_distribution": {
					"<40": 10,
					"41-60": 23,
					"61-80": 18,
					">80": 5
				},
				"gender_balance": {
					"male": 65,
					"female": 35
				},
				"pathogenicity": "pathogenic",
				"pathogenicity_level": "expert",
				"SVIP_status": "Reviewed",
				"clinical_significance": "predictive / prognostic",
				"significance_label": "A",
				"score": 4,
				"evidences": [
					{
						"drug": "Cetuximab",
						"evidence_type": "predictive",
						"clinical_significance": "resistant",
						"tier_level": "Tier II"
					},
					{
						"drug": "Vemurafenib",
						"evidence_type": "predictive",
						"clinical_significance": "sensitive",
						"tier_level": "Tier I"
					}
				]
			}
		]
	},
	{
		"gene_name": "BRAF",
		"variant_name": "V600E",
		"HGVScoding": "NM_004333.4:c.1799T>A",
		"HGVSprotein": "NP_004324.2:p.Val600Glu",
		"position": "GrCh37:chr7:140453136",
		"molecular_consequence": "NON_SYNONYMOUS",
		"tier_level": "1A",
		"dbSNP": "rs113488022",
		"SVIP_status": "Reviewed",
		"SVIP_confidence_score": 4,
		"variant_id": 1,
		"diseases": [
			{
				"name": "Papillary thyroid carcinoma",
				"nb_patients": "88/144",
				"age_distribution": {
					"<40": 5,
					"41-60": 30,
					"61-80": 50,
					">80": 3
				},
				"gender_balance": {
					"male": 60,
					"female": 40
				},
				"pathogenicity": "pathogenic",
				"pathogenicity_level": "automatic",
				"SVIP_status": "Curated",
				"clinical_significance": "predictive",
				"significance_label": "B",
				"score": 3,
				"evidences": [
					{
						"drug": "",
						"evidence_type": "Prognostic",
						"clinical_significance": "Poor outcome",
						"tier_level": "Tier II"
					},
					{
						"drug": "Vemurafenib",
						"evidence_type": "predictive",
						"clinical_significance": "sensitive",
						"tier_level": "Tier II"
					}
				]
			},
			{
				"name": "colorectal cancer",
				"nb_patients": "56/144",
				"age_distribution": {
					"<40": 10,
					"41-60": 23,
					"61-80": 18,
					">80": 5
				},
				"gender_balance": {
					"male": 65,
					"female": 35
				},
				"pathogenicity": "pathogenic",
				"pathogenicity_level": "expert",
				"SVIP_status": "Reviewed",
				"clinical_significance": "predictive / prognostic",
				"significance_label": "A",
				"score": 4,
				"evidences": [
					{
						"drug": "Cetuximab",
						"evidence_type": "predictive",
						"clinical_significance": "resistant",
						"tier_level": "Tier II"
					},
					{
						"drug": "Vemurafenib",
						"evidence_type": "predictive",
						"clinical_significance": "sensitive",
						"tier_level": "Tier I"
					}
				]
			}
		]
	},
	{
		"gene_name": "BRAF",
		"variant_name": "K601E",
		"HGVScoding": "NM_004333.4:c.1801A>G",
		"HGVSprotein": "NP_004324.2:p.Lys601Glu",
		"position": "GrCh37:chr7:140453134",
		"molecular_consequence": "NON_SYNONYMOUS",
		"tier_level": 2,
		"dbSNP": "rs121913364",
		"SVIP_status": "Curated",
		"SVIP_confidence_score": 3,
		"variant_id": 65,
		"diseases": [
			{
				"name": "Papillary thyroid carcinoma",
				"nb_patients": "88/144",
				"age_distribution": {
					"<40": 5,
					"41-60": 30,
					"61-80": 50,
					">80": 3
				},
				"gender_balance": {
					"male": 60,
					"female": 40
				},
				"pathogenicity": "pathogenic",
				"pathogenicity_level": "automatic",
				"SVIP_status": "Curated",
				"clinical_significance": "predictive",
				"significance_label": "B",
				"score": 3,
				"evidences": [
					{
						"drug": "",
						"evidence_type": "Prognostic",
						"clinical_significance": "Poor outcome",
						"tier_level": "Tier II"
					},
					{
						"drug": "Vemurafenib",
						"evidence_type": "predictive",
						"clinical_significance": "sensitive",
						"tier_level": "Tier II"
					}
				]
			},
			{
				"name": "colorectal cancer",
				"nb_patients": "56/144",
				"age_distribution": {
					"<40": 10,
					"41-60": 23,
					"61-80": 18,
					">80": 5
				},
				"gender_balance": {
					"male": 65,
					"female": 35
				},
				"pathogenicity": "pathogenic",
				"pathogenicity_level": "expert",
				"SVIP_status": "Reviewed",
				"clinical_significance": "predictive / prognostic",
				"significance_label": "A",
				"score": 4,
				"evidences": [
					{
						"drug": "Cetuximab",
						"evidence_type": "predictive",
						"clinical_significance": "resistant",
						"tier_level": "Tier II"
					},
					{
						"drug": "Vemurafenib",
						"evidence_type": "predictive",
						"clinical_significance": "sensitive",
						"tier_level": "Tier I"
					}
				]
			}
		]
	}
]
